Carisma Therapeutics
Financing Rounds
- Series B
- Public
- Exit
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.
Modality
- Cell Therapy
Indication
- Oncology
Development Status
- Phase 1